Skip to main content
. Author manuscript; available in PMC: 2017 Oct 12.
Published in final edited form as: Arthritis Rheumatol. 2014 Mar;66(3):497–507. doi: 10.1002/art.38268

Table 2. Prevalence of anti-CCP+, RF+ and ANA+ and age-adjusted death rates among women who reported RA at baseline or baseline and follow-up (N=5,657).

Anti-CCP RF ANA N Age-adjusted death rate/1000 PYs
- 5042 13.0 (11.5-14.7)
+ 612 21.4 (16.0-28.5)
- 4492 12.8 (11.2-14.6)
+ 1152 17.9 (14.4-22.4)
- 4768 13.7 (12.1-15.5)
+ 881 14.7 (11.3-19.4)
- - - 3802 12.5 (10.9-14.5)
+ - - 75 20.9 (9.9-48.3)
- + - 487 14.5 (10.0-21.1)
- - + 597 13.3 (9.4-18.9)
+ + - 395 23.3 (16.5-33.0)
+ - + 13 30.5 (7.9-136.8)
- + + 142 19.5 (11.2-36.0)
+ + + 128 14.4 (6.7-31.7)